Underwriter Warns Of Biotech Risks
NU Online News Service, May 29, 12:57 p.m. EST?Improper and inadequate procedures governing biotechnology companies' drug testing are exposing many of them to lawsuits, a New Jersey underwriter is warning.
"Inadequate informed consent forms, improper recruitment of test subjects, and potential conflicts of interest between clinical investigators and business partners leave many U.S. and Canadian biotechnology companies exposed to clinical trials litigation," according to Frank Goudsmit, a life sciences underwriting manager at Chubb & Son in Warren, N.J.
Recommended For You
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
